全球透皮贴剂市场 – 行业趋势和 2031 年预测

透皮贴剂市场分析和规模

在医疗领域的透皮贴剂市场中，这些贴剂利用透皮给药的概念，引入了一种变革性的药物输送方法。它们粘附在皮肤上，有助于将药物直接控制释放到血液中，提供持续的缓解并最大限度地减少副作用。透皮贴剂广泛应用于疼痛管理、激素替代疗法和尼古丁替代疗法，为传统口服药物提供了一种谨慎而方便的替代品。它们的功效延伸到预防晕动病、管理神经系统疾病和满足各种治疗需求，标志着透皮医疗治疗的重大进步。

2023 年全球透皮贴剂市场规模价值 74.8 亿美元，预计到 2031 年将达到 109.7 亿美元，2024 年至 2031 年预测期内的复合年增长率为 4.9%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

市场定义

透皮贴剂是一种贴在皮肤上的粘性贴剂，可使药物通过皮肤随时间推移进入血液。透皮贴剂是一种方便且可控的给药方式，可绕过消化系统并持续释放药物以达到持续的治疗效果。

透皮贴剂市场动态

驱动程序                                                                                          

• 吸烟人口增加导致透皮贴剂需求增加

The region's growing smoking population, as evidenced by the CDC's data indicating high usage rates among both high school and middle school students, underscores the escalating demand for smoking cessation aids like nicotine transdermal patches. With approximately 34.0% of high school students and 11.3% of middle school students having used tobacco products, including cigarettes, e-cigarettes, and other variants, there's a pressing need for effective strategies to combat nicotine addiction. Transdermal patches offer a viable solution, providing a discreet and gradual method for delivering nicotine replacement therapy. This surge in demand fueled by the youth demographic contributes significantly to the expansion of the transdermal patches market in the region.

• Increased Prevalence of Cancer Propels the Adoption of Transdermal Patches

The escalating incidence of breast and prostate cancer, as highlighted by reports like GLOBOCAN 2020, notably accelerates the growth trajectory of the transdermal patches market. With Mexico alone projecting a substantial increase in cancer cases over the coming decades, reaching 254,665 new cases by 2030 and 323,432 by 2040, and the demand for innovative drug delivery systems intensifies. Transdermal patches, particularly those containing medication nanoparticles tailored for cancer therapy-related pain management, stand poised to address this growing need. Their non-invasive nature and ability to provide controlled release make them an attractive option for patients grappling with pain associated with cancer treatments, further solidifying their role as a vital component in oncology care, specifically in the domain of transdermal patches for pain.

Opportunities

• Technological Advancements Propel Transdermal Patches to New Levels of Versatility

Innovations in patch design, materials, and drug delivery mechanisms continually enhance the efficacy, safety, and versatility of transdermal patches. These advancements enable the delivery of a broader range of drugs, including those with challenging physicochemical properties, expanding the market's scope across various therapeutic areas. Advancements in manufacturing processes improve scalability and reduce production costs, making transdermal patches more accessible to patients and healthcare providers. As technology evolves, it drives the development of novel patch-based delivery systems, stimulating market expansion and fostering a competitive landscape driven by innovation.

• Rising Healthcare Facility Investments lead to the Adoption of Transdermal Patches

With greater investment, healthcare facilities can afford to adopt and promote innovative drug delivery systems like transdermal patches. These investments enable facilities to enhance their infrastructure, procure advanced medical technologies, and expand their range of treatment options. As healthcare providers strive to improve patient care and outcomes, they increasingly embrace transdermal patches for their convenience and efficacy through improved medication adherence and management of chronic conditions. This growing investment creates a conducive environment for the widespread adoption and utilization of transdermal patches in various healthcare settings, thereby driving market expansion.

Restraints/Challenges

• High Product Cost Limits the Adoption of Transdermal Patches

Compared to conventional oral medications, transdermal patches often entail higher manufacturing expenses due to specialized formulation requirements and the need for precise drug delivery systems. The production of patches with advanced features, such as controlled-release mechanisms, can further increase production costs. These higher manufacturing costs may translate into elevated prices for consumers, potentially limiting their affordability and accessibility, particularly in healthcare systems with budget constraints. Consequently, addressing cost concerns is crucial for ensuring widespread adoption and equitable access to transdermal patches as a viable drug delivery option.

• Skin Irritation Affecting Patient Comfort Limits Transdermal Delivery Systems

Adhesive components or drug formulations in patches may trigger allergic reactions or irritate sensitive skin, limiting their use in specific individuals. This issue necessitates careful consideration of patch materials and formulations to minimize adverse skin reactions. Moreover, skin irritation can lead to discontinuation of treatment and loss of patient confidence in transdermal delivery systems.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, Adlarity, developed by Corium, debuted in the U.S. as a prescription medication. This once-weekly transdermal patch delivers consistent doses of donepezil, offering a convenient treatment option for patients with mild, moderate, or severe Alzheimer’s-related dementia. Its innovative delivery system aims to enhance patient compliance and improve therapeutic outcomes
• In 2022, the Luye Pharma Group received approval from China's National Medical Products Administration for their Rivastigmine Twice Weekly Transdermal Patch. This patch, designed for mild to moderate Alzheimer's symptoms, offers a convenient dosing schedule and aims to improve patient adherence. With its innovative transdermal delivery method, it represents a promising addition to Alzheimer's disease management in China

Transdermal Patches Market Scope

The market is segmented on the basis of product, type, application, technology, distribution channel, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Single-Layer Drug-In-Adhesive
• Multi-Layer Drug-In-Adhesive
• Matrix
• Reservoir
• Vapor
• Others

Type

• Fentanyl Transdermal Patch
• Nicotine Transdermal Patch
• Buprenorphine Transdermal Patch
• Clonidine Transdermal Patch
• Oxybutynin Transdermal Patch
• Others

Application

• Cardiovascular Disorder
• Central Nervous System Disorders (CNS)
• Pain Management/ Relief
• Smoking Reduction and Cessation Aid
• Overactive Bladder
• Nicotine Cessation
• Hormonal Therapy/ Disorders
• Dermatology
• Others

Technology

• Electric Current
• Mechanical Arrays
• Thermal Ablation
• Chemical Enhancers
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End User

• Home Care settings
• Hospitals
• Clinics

Transdermal Patches Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, product, type, application, technology, distribution channel, and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America is expected to dominate the market due to the region boasts a robust network of healthcare facilities, facilitating widespread access to treatment. Major players in the pharmaceutical industry have established a significant presence in North America, driving innovation and distribution. Additionally, the region's commitment to research and development in healthcare fuels continuous advancements, further solidifying its dominance in the market. These factors collectively contribute to North America's stronghold in the pharmaceutical landscape.

Asia-Pacific is expected to have substantial growth, driven by various factors. Government initiatives promoting healthcare awareness, coupled with expanding healthcare infrastructure, will catalyze this growth. Increased research activities further contribute to reaching the region's vast undiscovered markets and large population base. Moreover, the rising demand for quality healthcare services underscores the region's potential as a critical player in the global healthcare landscape.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Transdermal Patches Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• AdhexPharma (France)
• ProSolus, Inc (U.S.)
• tesa SE (Germany)
• Nitto Denko Corporation. (Japan)
• Noven Pharmaceuticals, Inc (U.S.)
• LTS Lohmann Therapie-Systeme AG (Germany)
• Medherant Limited (U.K.)
• Corium, LLC.（美国）
• 拜耳公司（德国）
• 诺华公司（瑞士）
• Antares Pharma（美国）
• 雅培（美国）
• Mylan NV（美国）
• Acrux Limited（澳大利亚）
• Sparsha Pharma International Pvt Ltd (印度)
• Bliss GVS Pharma.（印度）
• 强生服务公司（美国）
• Informa Connect Limited（英国）

SKU-28669